Abdominal diseases
Conditions
Interventions
Lidocaine group:Receive 2% intravenous lidocaine administered as 1.5 mg/kg bolus at induction of anesthesia followed by 1.5 mg/kg/h until the end of the surgery.
Placebo group:Receive a placebo (an equivalent volume of normal saline) bolus at induction of anesthesia followed until the end of the surgery.
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. undergoing elective laparoscopic or robot-assisted abdominal surgery. 2. ASA physical status I-III. 3. Ages 18-80 years.
Exclusion criteria
Exclusion criteria: 1. Language barrier or hearing impairment. 2. Arrhythmia: bradycardia, atrioventricular block, complete bundle branch block, prolonged QT interval, atrial fibrillation. 3. Kidney impairment (estimated glomerular filtration rate <30 mL/min/1.73 m^2). 4. Severe liver dysfunction (Child C or greater). 5. Allergy to lidocaine. 6. Inability to provide consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of emergence agitationafter general anesthesia for minimally invasive abdominal surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative pain score at rest and coughing pain;Morphine requirements after surgery;Catheter-related bladder discomfort (CRBD);Shivering;Postoperative nausea and vomiting (PONV) score;Cough;Ramsay Sedation Scale Score;Time to discharge from PACU;Time to verbal response;Time to extubation;Postoperative recovery;Time to walk after surgery;Time to readiness for discharge;Claviene-Dindo classification; | — |
Countries
China
Contacts
Public ContactHuifang Jiang
Zhejiang Cancer Hospital
Outcome results
None listed